Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.31 |
| ▸ | P4HB | P07237 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384271 | 0.82 | LIPG (0.39) | USP30SLC6A7P4HBROCK1 | |
| SCHEMBL16390870 | 0.82 | CHRM2 (0.35) | USP30SLC6A7P4HBROCK1 | |
| SCHEMBL14159644 | 0.82 | CHRM4 (0.33) | USP30SLC6A7 | |
| SCHEMBL26096649 | 0.81 | FFAR4 (0.35) | ROCK1 | |
| SCHEMBL3478584 | 0.81 | NR1H2 (0.39) | SLC6A7ROCK1 | |
| SCHEMBL26094735 | 0.81 | NOTUM (0.33) | SLC6A7 | |
| SCHEMBL26097421 | 0.81 | SLC6A9 (0.34) | USP30SLC6A7 | |
| SCHEMBL26096880 | 0.80 | CHRM2 (0.35) | — | |
| SCHEMBL26096238 | 0.79 | GRM1 (0.38) | USP30SLC6A7ROCK1 | |
| SCHEMBL19611363 | 0.79 | ROCK1 (0.42) | USP30P4HBROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | USP30 1694/4885SLC6A7 4732/4885P4HB 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.